MedicalDevice Licensing.com
Innovaro Pharmalicensing
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Innovaro Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Pay-per-Click New!
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Innovaro Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd
Innovaro Corporation
Out-licensing

Bioreactor Device and Method and System for Fabricating Tissue

National Institutes of Health (NIH)
A millifluidic bioreactor system for culturing, testing, and fabricating natural or engineered cells and tissues

Full description

Available for licensing and commercial development is a millifluidic bioreactor system for culturing, testing, and fabricating natural or engineered cells and tissues.  The system consists of a millifluidic bioreactor device and methods for sample culture.  Biologic samples that can be utilized include cells, scaffolds, tissue explants, and organoids.  The system is microchip controlled and can be operated in closed-loop, providing controlled delivery of medium and biofactors in a sterile temperature regulated environment under tabletop or incubator use.  Sample perfusion can be applied periodically or continuously, in a bidirectional or unidirectional manner, and medium re-circulated.

Advantages:

  • The device is small in size, and of conventional culture plate format.
  • Provides the ability to grow larger biologic samples than microfluidic systems, while utilizing smaller medium volumes than conventional bioreactors.  The bioreactor culture chamber is adapted to contain sample volumes on a milliliter scale (10 [mu]L to 1 mL, with a preferred size of 100 [mu]L), significantly larger than chamber volumes in microfluidic systems (on the order of 1 [mu]L).  Typical microfluidic systems are designed to culture cells and not larger tissue samples.
  • The integrated medium reservoirs and bioreactor chamber design provide for, (1) concentration of biofactors produced by the biologic sample, and (2) the use of smaller amounts of exogenous biofactor supplements in the culture medium. The local medium volume (within the vicinity of the sample) is less than twice the sample volume. The total medium volume utilized is small, preferably 2 ml, significantly smaller than conventional bioreactors (typically using 500-1000 mL).
  • Provides for real-time monitoring of sample growth and function in response to stimuli via an optical port and embedded sensors.  The optical port provides for microscopy and spectroscopy measurements using transmitted, reflected, or emitted (e.g., fluorescent, chemiluminescent) light.  The embedded sensors provide for measurement of culture fluid pressure and sample pH, oxygen tension, and temperature.
  • Capable of providing external stimulation to the biologic sample, including mechanical forces (e.g. fluid shear, hydrostatic pressure, matrix compression, microgravity via clinorotation), electrical fields (e.g., AC currents), and biofactors (e.g., growth factors, cytokines) while monitoring their effect in real-time via the embedded sensors, optical port, and medium sampling port.
  • Monitoring of biologic sample response to external stimulation can be performed non-invasively and non-destructively through the embedded sensors, optical port, and medium sampling port.  Testing of tissue mechanical and electrical properties (e.g., stiffness, permeability, loss modulus via stress or creep test, electrical impedance) can be performed over time without removing the sample from the bioreactor device.
  • The bioreactor sample chamber can be constructed with multiple levels fed via separate perfusion circuits, facilitating the growth and production of multiphasic tissues.  

Application:

Cartilage repair and methods for making tissue-engineered cartilage.

 

Development Status:

Electrospinning method is fully developed and cartilage has been synthesized. 

 

Patent information

PCT Application No. PCT/US2006/028417 filed 20 Jul 2006, which published as WO 2007/012071 on 25 Jan 2007; claiming priority to 20 Jul 2005 (HHS Reference No. E-042-2005/0-PCT-02)

U.S. Patent Application filed 18 Jan 2008 (HHS Reference No. E-042-2005/0-US-03)

 

Inventors:

Juan M. Taboas (NIAMS), Rocky S. Tuan (NIAMS), et al.

 

 

Type of business relationship sought

Licensees Sought:

Available for exclusive or non-exclusive licensing.

 

Licensing contact

Peter A. Soukas
Senior Licensing and Patenting Manager
Office of Technology Transfer

Contact directly

Company details

National Institutes of Health (NIH)

The NIH supports and conducts basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Innovaro Pharmalicensing current industry press releases.

© Copyright 1998-2010 Innovaro Pharmalicensing, a division of Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us